Objective. To explore whether tocilizumab + tapering MTX has comparable efficacy and safety vs tocilizumab + stable MTX in adult RA patients with inadequate response to MTX. Results. The study stopped early due to low recruitment, although the predetermined non-inferiority criteria were still met; 427 patients were enrolled to the open-label phase at week 0. At week 24, EULAR good/moderate response was achieved in 272 individuals (64.4%) who were randomized, 136 in each arm (36% withdrew/were not eligible). Additionally, 45.0% achieved DAS28 43.2, 33.5% achieved remission (DAS28 <2.6) and 64.2% had a DAS28 change 51.2. After week 24 randomization, the proportion of patients maintaining good/moderate EULAR response to week 60 was significantly greater for MTX taper vs stable MTX (76.5 vs 65.4%; P = 0.036), and since the lower limit of the 95% CI was >0.9, the pre-determined criteria for non-inferiority was fulfilled despite reduced recruitment. Safety analysis revealed no unexpected tocilizumab safety signals.
Introduction
RA is a chronic inflammatory disease resulting in the progressive destruction of joints [1, 2] accompanied by systemic manifestations affecting the skin, blood vessels and internal organs. If left untreated, RA can severely affect function, reduce health-related quality of life and increase mortality [1, 37] .
Current treatments comprise NSAIDs and DMARDs. Biologic DMARDs have been utilized to improve the short-and long-term outcomes. For many patients with severe RA and an inadequate response to standard DMARD treatment, therapy with a biologic DMARD and MTX is effective. However, approximately one-third of patients discontinue or are non-compliant with MTX because of preference or toxicity [812] , which provides a plausible explanation as to why registry and health care utilization data show that around one-third of RA patients receive their biologic agent as monotherapy [9, 1113] . The biologic DMARD tocilizumab has been shown to be effective as monotherapy in MTX-intolerant patients or patients for whom MTX was ineffective or inappropriate [8, 14] . The biologic DMARDs adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept have been shown to be as effective as monotherapy options and some are recommended in the UK National Institute for Health and Care Excellence guidelines for patients with severe active RA who have not responded to a combination of conventional DMARDs and are intolerant to MTX [15] . Many of these biologic DMARDs have better response rates when prescribed with MTX compared with monotherapy [16, 17] . However, there is evidence that tocilizumab can reduce the signs and symptoms of RA in combination with a conventional DMARD and as monotherapy [1821] . The ACT-RAY study reported that switching from MTX to tocilizumab was as effective as add-on therapy with tocilizumab to MTX in RA patients with an inadequate response to MTX [8, 22] .
MTX has been the cornerstone of RA therapy. However, in daily practice, frequent MTX-induced gastrointestinal disorders (such as nausea) have led to poor patient compliance [10, 23] . Furthermore, the use of MTX may lead to other safety issues, such as haematological and hepatic adverse events (AEs). These limitations highlight the importance of evaluating DMARD switching and tapering strategies to optimize the efficacy, safety and acceptability of biologic therapies.
The aim of this study was to investigate whether tocilizumab plus a tapering MTX dose had comparable efficacy and tolerability compared with tocilizumab plus a stable MTX dose in patients with severe active RA [28-joint DAS (DAS28) >5.1] and an inadequate response to MTX who had achieved a EULAR good/moderate response after 24 weeks of tocilizumab + MTX combination therapy.
Methods
This study (ACT-TAPER) was a randomized, placebocontrolled, non-inferiority study investigating the efficacy and safety of tapering MTX vs stable MTX in combination with tocilizumab in patients with severe active RA (DAS28 >5.1) with an inadequate response to DMARD treatment following achievement of a EULAR good/moderate response to tocilizumab + MTX combination therapy (supplementary Fig. S1 , available at Rheumatology Online).
The protocol was reviewed and approved by the Investigational Review Board and Ethics Committee (National Research Ethics Service Committee East of England-Cambridge South) and the study was conducted in full conformance with the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki. All patients provided written informed consent.
Patients
The study included male and female patients 518 years of age who fulfilled the EULAR/ACR criteria for the diagnosis of RA with ongoing active severe disease (DAS28 >5.1 on two occasions, 1 month apart) who had inadequately responded to a trial of two DMARDs, including MTX, and had not been previously treated with a biologic agent, such as a TNF inhibitor. Patients with a history of parenteral (s.c. or i.m.) MTX prior to the start of treatment were eligible but these patients must have been on a stable dose of oral MTX of at least 10 mg/week (no minimum duration of treatment).
Key exclusion criteria were major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization; a rheumatic autoimmune disease other than RA (including SLE, mixed CTD, scleroderma or PM) or significant systemic involvement secondary to RA (e.g. vasculitis, pulmonary fibrosis or Felty's syndrome); functional class IV RA as defined by the ACR Classification of Functional Status in RA (largely or wholly incapacitated with patient bedridden or confined to a wheelchair, permitting little or no self-care); prior history of or current inflammatory joint disease other than RA (e.g. gout, ReA, PsA, seronegative spondyloarthropathy, Lyme disease) and previous treatment with any biologic drug (e.g. TNF inhibitor) that is used in the treatment of RA. Table S1 , available at Rheumatology Online. Tapering occurred every 8 weeks until 0 mg was reached at week 48 or a disease flare occurred. If a flare occurred, the MTX dosage was increased by 5 mg every 8 weeks until the patient recovered; the stabilizing MTX dosage was maintained and no further tapering was done. If the required dosage of MTX after a flare was greater than the preweek 24 (pre-randomization) stable dose, the patient was considered a treatment failure and was discontinued from the study. Patients achieving adequate improvement stayed on treatment in their assigned treatment arm to week 72. Patients were assessed at clinic visits every 4 weeks from the start of treatment (week 0) and randomization (week 24) through to the end www.rheumatology.oxfordjournals.org of the study (week 72) and then received one further followup at week 76.
Endpoints
The primary endpoint was the proportion of patients maintaining good/moderate EULAR response (DAS28 score 43.2 and DAS28 improvement vs baseline >1.2; DAS28 score 43.2 and DAS28 improvement vs baseline >0.641.2 or DAS28 score >3.245.1 and DAS28 improvement vs baseline >0.641.2 or >1.2 or DAS28 score >5.1 and a DAS28 improvement vs baseline >1.2) from week 24 to 60 in the tocilizumab + tapering MTX vs tocilizumab + stable MTX group. Secondary efficacy endpoints included the change in DAS28 score from week 24 to 60 and 72, the proportion of patients achieving a reduction in DAS28 score 51.2 at week 60, the proportion of patients who achieved a DAS28 score 43.2, the proportion of patients in DAS28 remission (score <2.6) at weeks 60 and 72 and the number of disease flares at weeks 0 and 24 and follow-up. Disease flare was defined as an increase from randomization in DAS28 51.2 and a DAS28 >3.2 or as a DAS28 >5.1 regardless of the increase in DAS28. Safety was evaluated throughout by reporting of AEs and monitoring of vital signs and laboratory evaluations.
Statistical analyses
It was assumed that 85% of patients will maintain disease activity (either good or moderate EULAR response) from randomization (week 24) to week 60. If there was no difference between the two treatments, then 420 patients would be required to be 80% certain that the lower limit for the difference between the treatments of a one-sided 97.5% CI (or equivalently a 95% two-sided CI) was above the non-inferiority limit of À10% (or >0.9 if expressed as tocilizumab + tapering MTX:tocilizumab + stable MTX odds ratio). It was assumed that 20% of patients would drop out prior to randomization and 15% would drop out during the randomized phase, therefore the target number of patients for enrolment was 618, with 494 to reach randomization.
Primary and secondary efficacy analyses were conducted on the intention-to-treat population. The primary endpoint was analysed using logistic regression, stratified by baseline (week 24) EULAR response. Non-inferiority was concluded if the lower confidence limit was >0.9. Patients with a missing DAS28 at week 60 used their last post-baseline non-missing result in the analysis. All analyses of the secondary efficacy endpoints used a significance level of 5% and all hypotheses were created for superiority. No adjustments for multiplicity were performed; all hypotheses that were considered to be statistically significant must be interpreted from a medical perspective in order to be judged clinically relevant. Treatment differences and 95% CIs were calculated. Safety endpoints were presented descriptively.
Results
The study stopped early because of unexpectedly low recruitment and a higher than expected withdrawal rate; however, patient numbers were sufficient to allow analysis of the study objective (predetermined non-inferiority criteria were still met). In total, 427 patients entered the initial open-label phase of the study and 272 patients were randomized, 136 in each arm (the protocol required 494 patients to be randomized). Reasons for discontinuation were provided for 76 patients; the other 79 patients completed the initial phase but were not randomized, as the study was terminated prior to them entering the randomization phase. Patient disposition is shown in Fig. 1 and a summary of patient demographics and disease characteristics is shown in Table 1 . Demographic characteristics were balanced between treatment groups.
Efficacy
Of the initial (induction) phase population, 64.4% achieved good/moderate EULAR response at week 24, with 45.0% achieving DAS28 43.2, 33.5% remission (DAS28 <2.6) and 64.2% with DAS28 improvement 51.2. After week 24 randomization, the proportion of patients maintaining good/moderate EULAR response to week 60 was significantly greater with tocilizumab + tapering MTX vs tocilizumab + stable MTX (76.5 vs 65.4%; P = 0.036) (Fig. 2) ; the odds ratio (95% CI) of the proportion of patients maintaining good/moderate EULAR response to week 60 for tocilizumab + tapering MTX:tocilizumab + stable MTX was 1.803 (95% CI 1.037, 3.133), and since the lower limit of the 95% CI was >0.9, the predetermined criterion for noninferiority was fulfilled despite the reduced recruitment.
Results for the secondary efficacy endpoints are shown in Table 2 . The mean changes in DAS28 from week 24 to 60 (group A: À0.179; group B: À0.233) and from week 24 to 72 (group A: À0.105; group B: À0.224) showed no statistical differences between the two groups. Mean DAS28 data from week 0 to 72 for both treatment groups are shown in supplementary Fig. S2 , available at Rheumatology Online. Similarly, the proportion of patients achieving a DAS28 43.2, in remission, or with an improvement 51.2 in DAS28 at weeks 60 and 72 did not differ significantly between treatments ( Table 2) .
The number of disease flares, for the intention-to-treat population, decreased from week 24 [82 (30.1%)] to 72 [3 (4.1%)] with no difference in the incidence of disease flares being observed between the two treatment groups after randomization (Fig. 3) .
Safety
Safety analysis revealed no unexpected tocilizumab safety signals. Overall, 369/427 patients (86.4%) reported 1669 AEs during the initial phase and 196/272 patients (72.1%) reported 889 AEs during the randomized phase of the study. The proportion of patients reporting AEs was the same in both treatment groups during the randomized phase (72.1%). Of the AEs reported during the initial phase, 219/427 patients (51.3%) reported 442 events that were considered related to tocilizumab and 195/427 patients (45.7%) reported 386 events that were considered related to MTX. Of the AEs reported during the randomized phase, in the tocilizumab + tapering MTX group, 46 patients (33.8%) reported 80 events considered related to tocilizumab while 34 patients (25.0%) reported 63 events considered related to MTX; in the tocilizumab + stable MTX group, 45 patients (33.1%) reported 85 events considered related to tocilizumab while 38 patients (27.9%) reported 69 events considered related to MTX. Most AEs were grade 1 or 2 (mildmoderate) in initial intensity and most were resolved without clinical sequelae. No grade 4 or 5 AEs were reported. The most commonly reported AEs were nasopharyngitis, diarrhoea, mouth ulceration, upper and lower respiratory tract infection, headache, cough, oropharyngeal pain and arthralgia (Table 3) . Overall, 44 patients were withdrawn from the study because of an AE in the initial phase and 34 were withdrawn in the randomized phase (16 group A and 18 group B).
FIG. 1 Patient flow through the study
Sponsor termination describes patients withdrawn due to early study termination and not due to inefficacy, flare or adverse events. TCZ: tocilizumab. During the initial phase, 30/427 patients (7.0%) reported 37 serious AEs (SAEs), of which 21/427 patients (4.9%) reported 23 SAEs that were considered related to tocilizumab and 14/427 patients (3.3%) reported 16 SAEs that were considered related to MTX. All SAEs reported were of grades 13 (mildsevere) in intensity and most were resolved. Two patients died as a result of AEs; one patient during the initial phase (pre-randomization) died due to severe respiratory failure that was not considered related to either tocilizumab or MTX and one patient during the randomized phase in group A (double-blind tapering phase) died due to severe abdominal sepsis and pneumonia-the abdominal sepsis was considered related to tocilizumab but not to MTX and pneumonia was not considered related to either treatment.
Discussion
The ACT-TAPER study was undertaken to evaluate whether patients with severe active RA who had demonstrated a good response to MTX in combination with tocilizumab could maintain this response after MTX was tapered to zero compared with those where MTX was continued. Unfortunately, due to poor recruitment and a higher than expected withdrawal rate, the study had to be terminated early. Possible reasons for the poor recruitment include the duration of the study and challenges recruiting RA patients to a study where many reimbursed options exist in routine care. One possible explanation for the high withdrawal rate could be the inclusion of patients with ongoing active severe disease (DAS28 >5.1) who had inadequately responded to two DMARDs. However, despite this, evaluation of data from the 427 patients who participated in the study showed that tocilizumab with a tapering MTX dose was non-inferior to tocilizumab with continuing stable MTX at maintaining a good/moderate EULAR response in patients with active severe RA. The ability of tocilizumab to maintain the clinical effectiveness achieved when initiated in combination with MTX after MTX is tapered to zero is perhaps unsurprising as tocilizumab given in monotherapy has been shown to reduce the signs and symptoms of RA [1821, 24] . The ACT-RAY study compared the addition of tocilizumab to ongoing MTX with the switching of MTX to tocilizumab as monotherapy for patients with inadequate response to MTX alone and found that both strategies resulted in meaningful clinical and radiographic responses [8, 22] . These data raised the question of whether tapering the MTX dose may result in maintained efficacy and an improved safety profile for patients with inadequate response to MTX receiving combination therapy with tocilizumab.
RA is a chronic disease and hence patients with RA require long-term management to minimize their symptom burden and reduce or prevent the functional impairment and structural damage that can accumulate over time. While MTX has been the cornerstone of RA therapy, poor patient compliance is frequently reported in daily practice as a result of AEs [10, 23] . The introduction of biologic DMARDs in combination with MTX and as monotherapies has gone some way to improving tolerability and outcomes. An adaptive treatment approach in which therapy is optimized to the individual patients has been increasingly used to maximize efficacy and minimize drug intolerance to achieve and maintain defined disease activity targets [25] . For some patients, MTX presents an unacceptable burden of AEs, despite changing delivery to the s.c. route or increasing folic acid supplementation to 6 days/week. In this situation, the flexibility to reduce or withdraw MTX altogether without losing tocilizumab efficacy is highly desirable.
In the ACT-TAPER study, after the week 24 randomization, the proportion of patients maintaining good/moderate EULAR response to week 60 was greater for tocilizumab + MTX taper than tocilizumab + stable MTX, allowing the pre-determined criteria for non-inferiority to be fulfilled despite the reduced recruitment. Similarly, the mean changes in DAS28 from week 24 to 60 or week 72 and the proportion of patients achieving a DAS28 43.2, in remission or with a change in DAS28 51.2 at weeks 60 and 72 did not differ significantly between treatment groups. The protocol required discontinuation from the study for patients in the taper group who required a dose of MTX after a flare that was greater than the preweek 24 (pre-randomization) dose. In this eventuality, the patient was deemed a treatment failure and, as shown in Fig. 1 , there were no patients withdrawn for this reason. Therefore, in the taper arm, even when re-escalation had occurred, the dose of MTX always represented a reduction below that received prior to tapering.
Our findings suggest that after achieving a good/moderate EULAR response, tapering the MTX dose when in combination with tocilizumab is an appropriate strategy that is not likely to lead to loss of efficacy. While this is particularly attractive for patients experiencing AEs related to MTX, it may be appropriate for all patients. Indeed, in this study the taper arm comprised more (numerical) current smokers with a longer disease duration before study enrolment, which might have resulted in more resistant disease and a higher likelihood of flare in this treatment arm; this potentially increases the applicability of these findings to routine care.
There were no unexpected safety signals reported in this study. Tocilizumab and MTX therapy were generally well tolerated in both groups and there was no apparent difference between the treatment groups with regard to AE frequency, type or severity, nor were there any differences in laboratory assessments.
In conclusion, tapering MTX in patients with active severe RA who achieve a good/moderate EULAR response with tocilizumab + MTX combination therapy was non-inferior to continuing stable MTX + tocilizumab in maintaining a good/moderate EULAR response. This increases the treatment strategies available to patients with active severe RA and allows for individualized, tailored therapy.
